precision-medicine
(254)
Vertex Pharmaceuticals and the art of starting over
A hepatitis C blockbuster disappeared. A cystic fibrosis franchise took its place. Now Vertex is spending billions to see how often it can repeat the trick.
nference Wants Medicine to Read Its Own Notes
Hospitals have spent decades recording what happens to patients. nference is building the machinery to turn those scattered records into evidence - without asking hospitals to surrender control.
A2 Biotherapeutics teaches cancer fighters when to stop
A missing genetic marker is usually a gift to cancer. A2 Biotherapeutics is turning that absence into a target, with engineered T cells designed to attack tumors and spare healthy tissue.
Superluminal Medicines is betting on proteins that refuse to sit still
The Boston biotech designs drugs for receptors in motion. A Lilly partnership and a coming obesity trial will test how much that extra dimension is worth.
Magnet Biomedicine wants to give difficult proteins a useful introduction
Some proteins resist a drug’s advances. Magnet Biomedicine is recruiting a second protein to help - a molecular matchmaking strategy that has attracted $50 million in venture funding and an oncology agreement with Lilly.
Lifebit wants to move medicine forward. The data stays put.
The hard part of genomic research is often getting permission to use what already exists. Lifebit sends the tools to the data, turning institutional boundaries into something a researcher can work across.
Curve Biosciences Is Teaching a Blood Test Where to Look
Blood carries DNA from all over the body. Curve Biosciences is building a tissue atlas to sort out the return addresses, starting with chronic liver disease.
Precede Biosciences asks what cancer is doing now
A milliliter of plasma can carry clues to a tumor’s working life. Precede Biosciences is turning those clues into research tools for the medicines that need more than a mutation report.
PathAI’s big bet on the humble tissue slide
Roche agreed to pay $750 million upfront for a company that teaches computers to examine tissue. PathAI’s more revealing achievement is building a place where those computers and pathologists can work together.
Perspectum wants your MRI to put a number on disease
An Oxford spin-out turns MRI scans into measurements of organ health. Its harder task is proving that better numbers lead to better decisions - and are worth paying for.
Ontada finds cancer evidence in the everyday
The oncology business inside McKesson turns routine patient records into research material. Its advantage begins where the treatment happens - and its hardest work begins where the tidy fields end.
Seven Bridges and the Genome That Stayed Put
The clever move in genomics was to stop moving the data. Seven Bridges built a business bringing researchers, workflows and rented computing power to the same place - and now carries that idea into Velsera.
Magnus and the fifty-minute pause
A five-day depression treatment sounds like a story about speed. Magnus Medical’s SAINT system makes a more interesting wager: where you stimulate the brain, and when you stop, can matter as much as how hard you try.
The Button That Asked Medicine to Remember
Atropos Health began with a Stanford physician’s question: what can the records of past patients teach us about the person in front of us? Its answer grew from a 48-hour consult into a system that puts real-world evidence inside clinical and research workflows.
The Trial Is Open. Why Can’t the Patient Get In?
Trial Library has built a business around an awkward truth in cancer care: a trial can exist, a patient can qualify, and the two may still never meet. Its answer starts with the oncologist and continues long after the search result.
Biostate AI Made the Data Cheaper. Then the Data Became the Problem.
A Houston biotech cut the cost of reading RNA, only to find its scientists swamped by the results. The tool it built to catch up may be the more revealing business.
The Drug Targets Hiding in Plain Sight
BridGene built a way to watch drug-like molecules meet proteins inside living cells. The wager is that the so-called undruggable proteome is not impossible - merely badly observed.
Venky Soundararajan and the Case of the Missing Medical Signal
A biological engineer trained to read proteins now builds machines that read the unruly archive of medicine. His wager is simple to state and difficult to execute: the next useful discovery may already be hiding in the record.
Jim Robinson and the Art of the Two-Signal Bet
A salesman's instinct for people brought Jim Robinson to the edge of cell therapy. At A2 Bio, his job is to turn a biological logic gate into an organization that can deliver on it.
The Tiny Lymph Nodes Making a Very Large Bet
Parallel Bio grows repeatable human immune systems in dishes, lets robots run the experiments, and asks a blunt question: why wait for a clinical trial to learn that mice are not people?
The Weight-Loss Company Betting the Answer Is Not Just a Drug
Ilant Health began with a surprisingly ordinary failure: a patient had to find her own obesity care. Now it is trying to turn treatment matching, human support and financial accountability into one coherent benefit.
GeneOnline Turned Biotech News Into a Map for Finding the Next Deal
The bilingual publisher spent years explaining Asian biotech to the world. Then it packaged the map behind the reporting into BIODND - an AI-assisted database built for the people hunting companies, capital and partners.
Nikole Kimes Took the Scenic Route to the CEO’s Chair
She studied coral ecosystems, joined the Peace Corps and went looking for a science that could hold all her interests at once. Then a UCSF discovery turned a self-described meandering career into a lesson in how founders are really made: one unfamiliar job at a time.
Pek Lum Keeps Asking Biology Better Questions
Before AI became biotech's favorite phrase, Pek Lum was teaching computers to notice what biology hides in plain sight. At Auransa, that long apprenticeship has become a patient-first method for finding the signal inside human complexity.
Ilsong Lee’s Second Act Is Making Research Less Mechanical
After decades spent turning complex semiconductor systems into businesses, Cipherome’s CEO is applying the same operational instinct to the messier machinery of clinical and genomic data.
Giordano Bottà Left Oxford to Put a Number on the Invisible
A mosquito-genomics researcher spotted a stubborn gap between scientific discovery and useful software. He packed up in Oxford, returned to Rome, and began the long work of making inherited risk legible in the clinic.
CareDx Made Transplant Care Less Invasive. Then Its Own Business Needed Surgery.
The transplant diagnostics company turned fragments of donor DNA into a recurring-care business. A 2023 reimbursement shock forced a reset - and revealed a playbook built on narrow markets, repeat tests, and one very deep customer relationship.
Scott Marshall Is Making Clinical Trial Data Behave
The QuartzBio CEO built his career around an unglamorous but expensive problem: a clinical sample can travel farther than the data that explains it. His answer is a connected system designed to catch the gaps before researchers have to play another round of spreadsheet detective.
Bobby Reddy Bet a Decade on the Data Hospitals Were Missing
An all-access hospital badge helped an electrical engineer discover that his clever device was solving the wrong problem. What followed was a ten-year lesson in listening, clinical rigor and the unglamorous patience required to make AI useful.
Patrick Roberts Is Betting the Cell Cycle Has Another Door
After helping a small North Carolina biotech move a cell-cycle drug from discovery toward patients, Patrick Roberts reunited with longtime colleagues to pursue a harder target: CDK2. The wager behind Incyclix Bio is that precision, patience and the right biomarkers can reopen a route that resistant cancers have learned to use.